Biotechnology Investment Incentive Tax Credit - Conversion to Grant Program
Summary
HB400 converts Maryland’s Biotechnology Investment Incentive Tax Credit into the Biotechnology Investment Incentive Grant Program, moving the program from the Tax-General Article to the Economic Development Article and placing administration with the Department of Commerce. Under the bill, qualified investors in qualified Maryland biotechnology companies would no longer receive a tax credit to claim on a return; instead, they would receive a grant after the Department verifies the investment. The bill keeps the core eligibility framework largely intact, including the minimum $25,000 investment threshold, limits on investor ownership, company size and age requirements, and the requirement that the company be headquartered and operating in Maryland.
The bill also creates a dedicated Biotechnology Investment Incentive Grant Program Fund and requires a $10 million annual appropriation to that fund, with grants to be disbursed within 90 days after the Department determines the investment was made. It preserves the program’s first-come, first-served application process, caps awards by company and fiscal year, and continues recapture/revocation rules if the investor sells the interest too soon, the company ceases operating in Maryland, or the company fails to meet qualification requirements within two months. HB400 also updates related opportunity zone provisions and adds Maryland income tax subtraction modifications so grants received under the program are not taxed again at the state level.
Impact
HB400 would substantially revise Maryland’s biotechnology incentive structure by replacing a tax credit mechanism with a grant-based economic development program. It transfers statutory provisions from the Tax-General Article to a new subtitle in the Economic Development Article, changes references throughout the code, repeals the old tax-credit provision for future issuances, and adds conforming changes to opportunity zone enhancement rules and state income tax subtraction provisions for individuals and corporations. The bill also requires the Department of Commerce to administer the program and adopt regulations, while preserving prior-law treatment for certificates issued before the effective date.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears policy-supportive and programmatic rather than contentious. The bill is framed as a modernization of an existing incentive, with the stated goal of fostering biotechnology growth, encouraging early-stage investment, and increasing the number of life sciences investors in Maryland. The structure suggests an effort to make the incentive more direct and administratively efficient by converting the benefit into a grant.
Contention
The main potential points of contention are fiscal and administrative. The bill commits the State to a $10 million annual appropriation and removes the prior tax-credit model, which may raise questions about budget impact, program oversight, and whether grants are preferable to credits. Another possible issue is the continued concentration of benefits in a narrow set of early-stage biotechnology firms, including geographic preferences for certain counties and regional enterprise zones. The recapture provisions and strict eligibility rules also indicate concern about preventing abuse and ensuring companies remain in Maryland, but no specific opposition or support is documented in the provided discussion materials.